Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

Vanda Revenue Climbs 24%, but Cash Burn Raises Liquidity Questions for VNDA Investors

Vanda’s Q3 revenue rose 24%, but a $123.4 million liquidity decline and higher expected cash burn complicate the Nasdaq-listed stock’s outlo…

Nov 1, 2026
Pharmaceutical

AbbVie Raises Full-Year Outlook After Q3 Beat as Skyrizi Pipeline Expands

AbbVie beat Q3 2026 estimates and raised its full-year outlook while advancing Skyrizi combinations and reporting positive CERVINO results.

Nov 1, 2026
Pharmaceutical

AstraZeneca ADR Jumps 7% After Q3 Beat as Tagrisso and Baxfendy Drive Momentum

AstraZeneca's Nasdaq-listed ADR rose 7% after a Q3 beat, with Tagrisso sales and respiratory pipeline progress supporting the outlook.

Nov 1, 2026
Pharmaceutical

Inovio Stock Surges After FDA Clears First Product as Precigen Shares Sink

Inovio's first FDA approval triggered a sharp stock reaction, while Precigen shares fell as investors reassessed the RRP competitive landsca…

Oct 31, 2026
Pharmaceutical

Acumen Pharmaceuticals Downgraded After Sabirnetug Fails Phase 2 Alzheimer’s Trial

Acumen’s ABOS faces a major biotech catalyst after sabirnetug missed key Phase 2 endpoints, prompting a Stifel downgrade.

Oct 30, 2026
Pharmaceutical

Regeneron Jumps 12% as Dupixent Royalties and Eylea HD Fuel Earnings Beat

Regeneron surged 12% after an earnings beat, powered by Dupixent royalties, Eylea HD sales, buybacks, cash and a December dividend.

Oct 30, 2026
Pharmaceutical

FDA Delays Mitapivat Sickle Cell Decision Until February 2027

The FDA extended its mitapivat review to February 2027, pushing a key regulatory and commercial catalyst further into the future.

Oct 30, 2026
Pharmaceutical

Sun Pharma’s Ilumya Wins FDA Approval for Psoriatic Arthritis

FDA approval for Ilumya in active psoriatic arthritis broadens Sun Pharma’s U.S. immunology opportunity while intensifying the biologics foc…

Oct 30, 2026
Pharmaceutical

NRx Pharmaceuticals Shares Jump 15% After Early FDA Approval for Preservative-Free Ketamine

NRx Pharmaceuticals won early FDA approval for preservative-free ketamine, sending NRXP shares approximately 15% higher premarket.

Oct 30, 2026
Pharmaceutical

Mineralys’ Positive CKD Data Expands the Investment Case for Lorundrostat

Positive Phase 2 CKD data may broaden lorundrostat’s commercial potential and sharpen investor interest in Mineralys Therapeutics.

Oct 29, 2026
Pharmaceutical

SELLAS AML Trial Milestone Brings SLS Shares Closer to a High-Stakes Data Readout

SELLAS says its Phase 3 REGAL trial reached a statistical milestone, setting up preliminary topline data as a major catalyst for $SLS.

Oct 29, 2026
Pharmaceutical

Geron’s Imetelstat Myelofibrosis Trial Puts a Major Biotech Catalyst Back in Focus

Geron’s Phase 3 IMpactMF update places imetelstat at the center of a potentially binary catalyst for $GERN and its pipeline valuation.

Oct 29, 2026